

Hans-Christoph Diener

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533480/publications.pdf>

Version: 2024-02-01

244
papers

40,726
citations

10351

72
h-index

2439

197
g-index

276
all docs

276
docs citations

276
times ranked

28398
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151. | 13.9 | 9,839 |
| 2 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962. | 1.0 | 5,689 |
| 3 | Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 331-337. | 6.3 | 2,110 |
| 4 | Cryptogenic Stroke and Underlying Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2014, 370, 2478-2486. | 13.9 | 1,694 |
| 5 | Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. <i>Lancet, The</i> , 2016, 388, 761-775. | 6.3 | 1,414 |
| 6 | Embolic strokes of undetermined source: the case for a new clinical construct. <i>Lancet Neurology, The</i> , 2014, 13, 429-438. | 4.9 | 1,268 |
| 7 | Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372. | 1.6 | 1,035 |
| 8 | Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. <i>New England Journal of Medicine</i> , 2008, 359, 1238-1251. | 13.9 | 882 |
| 9 | OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. <i>Cephalalgia</i> , 2010, 30, 793-803. | 1.8 | 797 |
| 10 | OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. <i>Cephalalgia</i> , 2010, 30, 804-814. | 1.8 | 795 |
| 11 | OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-blind, Randomized, Placebo-controlled Phases of the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 921-936. | 1.8 | 779 |
| 12 | Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. <i>Cephalalgia</i> , 2000, 20, 765-786. | 1.8 | 615 |
| 13 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2019, 380, 1906-1917. | 13.9 | 568 |
| 14 | Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517. | 1.0 | 385 |
| 15 | Gray matter decrease in patients with chronic tension type headache. <i>Neurology</i> , 2005, 65, 1483-1486. | 1.5 | 381 |
| 16 | Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. <i>Lancet Neurology, The</i> , 2006, 5, 310-316. | 4.9 | 377 |
| 17 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. <i>Lancet, The</i> , 2016, 388, 365-375. | 6.3 | 321 |
| 18 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. <i>Lancet Neurology, The</i> , 2008, 7, 875-884. | 4.9 | 310 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinical features of withdrawal headache following overuse of triptans and other headache drugs. <i>Neurology</i> , 2001, 57, 1694-1698. | 1.5 | 283 |
| 20 | Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. <i>Lancet</i> , The, 2019, 394, 1030-1040. | 6.3 | 269 |
| 21 | Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832. | 1.8 | 245 |
| 22 | The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785. | 1.2 | 244 |
| 23 | NXY-059 for the Treatment of Acute Stroke. <i>Stroke</i> , 2008, 39, 1751-1758. | 1.0 | 222 |
| 24 | Medication Overuse Headache: Rates and Predictors for Relapse in a 4-year Prospective Study. <i>Cephalalgia</i> , 2005, 25, 12-15. | 1.8 | 204 |
| 25 | BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. <i>Cephalalgia</i> , 2011, 31, 573-584. | 1.8 | 204 |
| 26 | Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058. | 1.0 | 203 |
| 27 | Safety and Efficacy of Dabigatran Etxilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis. <i>JAMA Neurology</i> , 2019, 76, 1457. | 4.5 | 200 |
| 28 | Medication-overuse headache: risk factors, pathophysiology and management. <i>Nature Reviews Neurology</i> , 2016, 12, 575-583. | 4.9 | 197 |
| 29 | Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021, 17, 501-514. | 4.9 | 194 |
| 30 | The Fixed Combination of Acetylsalicylic acid, Paracetamol and Caffeine is more Effective than Single Substances and Dual Combination for the Treatment of Headache: a Multicentre, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Parallel Group Study. <i>Cephalalgia</i> , 2005, 25, 776-787. | 1.8 | 193 |
| 31 | Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1543-1552. | 1.6 | 190 |
| 32 | Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1804-1818. | 1.2 | 189 |
| 33 | OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013, 331, 48-56. | 0.3 | 168 |
| 34 | Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320. | 1.5 | 163 |
| 35 | Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710. | 1.8 | 154 |
| 36 | Predictors for atrial fibrillation detection after cryptogenic stroke. <i>Neurology</i> , 2016, 86, 261-269. | 1.5 | 153 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902. | 4.9 | 151 |
| 38 | Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003333. | 2.1 | 149 |
| 39 | Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus). <i>International Journal of Stroke</i> , 2015, 10, 1309-1312. | 2.9 | 147 |
| 40 | New therapeutic approaches for the prevention and treatment of migraine. <i>Lancet Neurology</i> , The, 2015, 14, 1010-1022. | 4.9 | 144 |
| 41 | Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 1054-1062. | 4.9 | 136 |
| 42 | Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1. | 0.6 | 135 |
| 43 | Atrial Fibrillation and Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2019, 73, 612-619. | 1.2 | 133 |
| 44 | Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. <i>Neurology</i> , 2003, 60, 1682-1683. | 1.5 | 132 |
| 45 | OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. <i>Neurology</i> , 2011, 77, 1465-1472. | 1.5 | 130 |
| 46 | Chronic migraine—classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171. | 4.9 | 130 |
| 47 | My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. <i>Journal of Headache and Pain</i> , 2018, 19, 115. | 2.5 | 130 |
| 48 | The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria. <i>European Neurology</i> , 2004, 51, 89-97. | 0.6 | 128 |
| 49 | Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. <i>EuroIntervention</i> , 2018, 14, e590-e597. | 1.4 | 127 |
| 50 | Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. <i>Journal of Headache and Pain</i> , 2011, 12, 475-483. | 2.5 | 125 |
| 51 | Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021. | 1.0 | 125 |
| 52 | COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. <i>Annals of Neurology</i> , 2021, 90, 627-639. | 2.8 | 122 |
| 53 | Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141. | 0.7 | 120 |
| 54 | Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot®) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison. <i>European Neurology</i> , 2002, 47, 99-107. | 0.6 | 118 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Guidelines for Controlled Trials of Drugs in Tension-Type Headache: Second Edition. <i>Cephalalgia</i> , 2010, 30, 1-16. | 1.8 | 118 |
| 56 | Migraine, migraine aura, and cervical artery dissection: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2011, 31, 886-896. | 1.8 | 113 |
| 57 | Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225. | 1.0 | 112 |
| 58 | Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069. | 1.0 | 106 |
| 59 | Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 996-1001. | 0.9 | 105 |
| 60 | Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044. | 1.8 | 105 |
| 61 | Left atrial appendage occlusion with the Amplatzerâ„¢ Amuletâ„¢ device: full results of the prospective global observational study. <i>European Heart Journal</i> , 2020, 41, 2894-2901. | 1.0 | 102 |
| 62 | Cerebellar Dysfunction of Movement and Perception. <i>Canadian Journal of Neurological Sciences</i> , 1993, 20, S62-S69. | 0.3 | 99 |
| 63 | European headache federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015, 17, 5. | 2.5 | 97 |
| 64 | Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. <i>Lancet, The</i> , 2018, 391, 2019-2027. | 6.3 | 96 |
| 65 | Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2006, 21, 279-293. | 0.8 | 94 |
| 66 | Unbalanced Randomization Influences Placebo Response: Scientific Versus Ethical Issues Around the Use of Placebo in Migraine Trials. <i>Cephalalgia</i> , 1999, 19, 699-700. | 1.8 | 86 |
| 67 | Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017, 129, 2980-2987. | 0.6 | 85 |
| 68 | Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388. | 1.8 | 84 |
| 69 | A Comparative Study Of Oral Acetylsalicylic Acid and Metoprolol for the Prophylactic Treatment of Migraine. A Randomized, Controlled, Double-Blind, Parallel Group Phase III Study. <i>Cephalalgia</i> , 2001, 21, 120-128. | 1.8 | 82 |
| 70 | Vestibular migraine. <i>Cephalalgia</i> , 2015, 35, 262-270. | 1.8 | 81 |
| 71 | Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany â€” A national case collection. <i>International Journal of Stroke</i> , 2017, 12, 383-391. | 2.9 | 80 |
| 72 | Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2013, 33, 202-207. | 1.8 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021, 7, 24. | 18.1 | 75 |
| 74 | Central vestibular system modulation in vestibular migraine. <i>Cephalalgia</i> , 2014, 34, 1053-1061. | 1.8 | 74 |
| 75 | Caffeine in the management of patients with headache. <i>Journal of Headache and Pain</i> , 2017, 18, 107. | 2.5 | 73 |
| 76 | Seizure-Associated Headache in Epilepsy. <i>Epilepsia</i> , 2002, 42, 1176-1179. | 2.6 | 72 |
| 77 | Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643. | 1.0 | 69 |
| 78 | Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487. | 1.8 | 69 |
| 79 | European Academy of Neurology guideline on the management of medication overuse headache. <i>European Journal of Neurology</i> , 2020, 27, 1102-1116. | 1.7 | 69 |
| 80 | Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. <i>International Journal of Stroke</i> , 2016, 11, 302-312. | 2.9 | 64 |
| 81 | Prevention of medication overuse in patients with migraine. <i>Pain</i> , 2010, 151, 404-413. | 2.0 | 63 |
| 82 | Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (Ö-KSG) and the Schweizerische Kopfwehrgesellschaft (SKG). <i>Journal of Headache and Pain</i> , 2011, 12, 201-217. | 2.5 | 62 |
| 83 | Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data. <i>Cerebrovascular Diseases</i> , 2004, 17, 253-261. | 0.8 | 61 |
| 84 | DP-b99, a Membrane-Activated Metal Ion Chelator, as Neuroprotective Therapy in Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1774-1778. | 1.0 | 61 |
| 85 | A Practical Guide to the Management and Prevention of Migraine. <i>Drugs</i> , 1998, 56, 811-824. | 4.9 | 60 |
| 86 | Cortical plasticity in episodic and chronic cluster headache. <i>NeuroImage: Clinical</i> , 2014, 6, 415-423. | 1.4 | 58 |
| 87 | Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. <i>International Journal of Stroke</i> , 2017, 12, 9-12. | 2.9 | 57 |
| 88 | Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication overuse headache: Subgroup analysis of PROMISE 2. <i>Headache</i> , 2021, 61, 125-136. | 1.8 | 55 |
| 89 | Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany: Updated series of 120 cases. <i>International Journal of Stroke</i> , 2020, 15, 609-618. | 2.9 | 54 |
| 90 | Efficacy of 1,000 mg Effervescent Acetylsalicylic Acid and Sumatriptan in Treating Associated Migraine Symptoms. <i>European Neurology</i> , 2004, 52, 50-56. | 0.6 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Patent foramen ovale, stroke, and cardiovascular disease in migraine. <i>Current Opinion in Neurology</i> , 2007, 20, 310-319. | 1.8 | 53 |
| 92 | Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016, 178, 145-150. | 1.2 | 52 |
| 93 | Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: Results of the German Headache Consortium study. <i>Pain</i> , 2013, 154, 484-492. | 2.0 | 50 |
| 94 | Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care: the Dizziness and Vertigo Registry (DiVeR) Study. <i>Journal of Neurology</i> , 2015, 262, 2083-2091. | 1.8 | 50 |
| 95 | Detoxification for medication overuse headache is not necessary. <i>Cephalalgia</i> , 2012, 32, 423-427. | 1.8 | 49 |
| 96 | Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. <i>Journal of Pain</i> , 2015, 16, 164-175. | 0.7 | 49 |
| 97 | Cerebral gray matter changes in persistent postural perceptual dizziness. <i>Journal of Psychosomatic Research</i> , 2017, 103, 95-101. | 1.2 | 47 |
| 98 | Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. <i>International Journal of Clinical Practice</i> , 2002, 56, 243-6. | 0.8 | 45 |
| 99 | Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2011, 15, 64-69. | 1.3 | 43 |
| 100 | Involvement of the human medial cerebellum in long-term habituation of the acoustic startle response. <i>Experimental Brain Research</i> , 2000, 133, 359-367. | 0.7 | 42 |
| 101 | Patent foramen ovale and migraine: no reason to intervene. <i>Journal of Headache and Pain</i> , 2007, 8, 3-6. | 2.5 | 42 |
| 102 | Medication Overuse Headache*. <i>Current Medical Research and Opinion</i> , 2001, 17, s17-21. | 0.9 | 41 |
| 103 | Aspirin in the treatment of acute migraine attacks. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 563-573. | 1.4 | 41 |
| 104 | The European Stroke Organisation Guidelines: a standard operating procedure. <i>International Journal of Stroke</i> , 2015, 10, 128-135. | 2.9 | 41 |
| 105 | An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial. <i>Lancet, The</i> , 2019, 394, 219-229. | 6.3 | 41 |
| 106 | Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 786-803. | 1.2 | 40 |
| 107 | Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. <i>Lancet Neurology, The</i> , 2021, 20, 29-37. | 4.9 | 38 |
| 108 | Persistent Postural-Perceptual Dizziness: A Matter of Higher, Central Dysfunction?. <i>PLoS ONE</i> , 2015, 10, e0142468. | 1.1 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | A personal view of the classification and definition of drug dependence headache. <i>Cephalalgia</i> , 1993, 13, 68-71. | 1.8 | 37 |
| 110 | Patent foramen ovale and migraine. <i>Current Pain and Headache Reports</i> , 2007, 11, 236-240. | 1.3 | 36 |
| 111 | Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. <i>Cephalalgia</i> , 2019, 39, 803-816. | 1.8 | 36 |
| 112 | Patent foramen ovale: paradoxical connection to migraine and stroke. <i>Current Opinion in Neurology</i> , 2005, 18, 299-304. | 1.8 | 35 |
| 113 | Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. <i>Neurological Research and Practice</i> , 2020, 2, 11. | 1.0 | 35 |
| 114 | Medication Overuse Headache. <i>Drug Safety</i> , 2001, 24, 921-927. | 1.4 | 33 |
| 115 | Migraine-associated risks and comorbidity. <i>Journal of Neurology</i> , 2008, 255, 1290-1301. | 1.8 | 33 |
| 116 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). <i>International Journal of Clinical Practice</i> , 2001, 55, 162-3. | 0.8 | 33 |
| 117 | Antimigraine drugs. <i>Journal of Neurology</i> , 1999, 246, 515-519. | 1.8 | 32 |
| 118 | Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. <i>Circulation</i> , 2021, 144, 1738-1746. | 1.6 | 31 |
| 119 | Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study. <i>Cephalalgia</i> , 2001, 21, 66-70. | 1.8 | 30 |
| 120 | Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). <i>American Heart Journal</i> , 2019, 211, 45-53. | 1.2 | 30 |
| 121 | Investigation on the mitochondrial transfer RNA ^{Leu} (UUR) in blood cells from patients with cluster headache. <i>Journal of Neurology</i> , 1996, 243, 305-307. | 1.8 | 28 |
| 122 | Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018, 131, 945-955.e3. | 0.6 | 27 |
| 123 | Hypnic Headache: Clinical Course and Treatment. <i>Current Treatment Options in Neurology</i> , 2012, 14, 15-26. | 0.7 | 26 |
| 124 | Review and update of the concept of embolic stroke of undetermined source. <i>Nature Reviews Neurology</i> , 2022, 18, 455-465. | 4.9 | 26 |
| 125 | Antithrombotic secondary prevention after stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2002, 4, 429-440. | 0.4 | 25 |
| 126 | Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis. <i>Stroke</i> , 2020, 51, 3344-3347. | 1.0 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Treatment of Migraine Attacks with Intranasal Alniditan: An Open Study. <i>Cephalalgia</i> , 2001, 21, 140-144. | 1.8 | 24 |
| 128 | The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. <i>European Journal of Neurology</i> , 2004, 11, 125-134. | 1.7 | 24 |
| 129 | Sphenopalatine Ganglion Stimulation to Augment Cerebral Blood Flow. <i>Stroke</i> , 2019, 50, 2108-2117. | 1.0 | 24 |
| 130 | The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving $\geq 50\%$, $\geq 75\%$, and 100% response. <i>Cephalalgia</i> , 2020, 40, 28-38. | 1.8 | 24 |
| 131 | Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i> , 2021, 41, 279-293. | 1.8 | 24 |
| 132 | Dipyridamole trials in stroke prevention. <i>Neurology</i> , 1998, 51, S17-9. | 1.5 | 23 |
| 133 | Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. <i>Journal of Hypertension</i> , 2009, 27, S31-S36. | 0.3 | 23 |
| 134 | Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS). <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 64. | 2.0 | 23 |
| 135 | Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis. <i>International Journal of Stroke</i> , 2018, 13, 766-770. | 2.9 | 23 |
| 136 | Antithrombotic Treatment of Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 1758-1765. | 1.0 | 23 |
| 137 | Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale. <i>Stroke</i> , 2021, 52, 1065-1068. | 1.0 | 23 |
| 138 | Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2020, 22, I13-I21. | 0.0 | 23 |
| 139 | Predicting recovery after intracerebral hemorrhage – An external validation in patients from controlled clinical trials. <i>Journal of Neurology</i> , 2009, 256, 464-469. | 1.8 | 22 |
| 140 | CGRP as a new target in prevention and treatment of migraine. <i>Lancet Neurology</i> , The, 2014, 13, 1065-1067. | 4.9 | 22 |
| 141 | Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. <i>International Journal of Stroke</i> , 2022, 17, 189-197. | 2.9 | 22 |
| 142 | Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. <i>Headache</i> , 2021, 61, 1421-1431. | 1.8 | 22 |
| 143 | The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Cephalalgia</i> , 2001, 21, 672-679. | 1.8 | 21 |
| 144 | The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573. | 1.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Atrial Fibrillation and Microbleeds. <i>Stroke</i> , 2017, 48, 2660-2664. | 1.0 | 20 |
| 146 | Polarity-specific modulation of pain processing by transcranial direct current stimulation – a blinded longitudinal fMRI study. <i>Journal of Headache and Pain</i> , 2018, 19, 99. | 2.5 | 20 |
| 147 | The Risks or Lack Thereof of Migraine Treatments in Vascular Disease. <i>Headache</i> , 2020, 60, 649-653. | 1.8 | 20 |
| 148 | Correlation between Clinical Outcomes and Baseline CT and CT Angiographic Findings in the SWIFT PRIME Trial. <i>American Journal of Neuroradiology</i> , 2017, 38, 2270-2276. | 1.2 | 19 |
| 149 | Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151. | 1.8 | 19 |
| 150 | Does atrial fibrillation lead to cognitive decline and dementia?. <i>European Heart Journal</i> , 2017, 38, 2619-2620. | 1.0 | 18 |
| 151 | Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. <i>American Heart Journal</i> , 2019, 218, 123-127. | 1.2 | 18 |
| 152 | Stroke prevention in atrial fibrillation. <i>Current Opinion in Neurology</i> , 2012, 25, 27-35. | 1.8 | 15 |
| 153 | Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies. <i>Journal of Headache and Pain</i> , 2014, 15, 76. | 2.5 | 15 |
| 154 | Headache research in 2015: progress in migraine treatment. <i>Lancet Neurology</i> , The, 2016, 15, 4-5. | 4.9 | 15 |
| 155 | Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1597-1602. | 0.9 | 15 |
| 156 | Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692. | 0.8 | 15 |
| 157 | COVID-19: patients with stroke or risk of stroke. <i>European Heart Journal Supplements</i> , 2020, 22, P25-P28. | 0.0 | 15 |
| 158 | Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 560-573. | 1.5 | 15 |
| 159 | No Pattern Alteration in Single Nocturnal Melatonin Secretion in Patients With Hypnic Headache: A Case-Control Study. <i>Headache</i> , 2017, 57, 648-653. | 1.8 | 14 |
| 160 | Eletriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 43-53. | 1.4 | 13 |
| 161 | Migraine – the forgotten epidemic: development of the EHF/WHA Rome Declaration on Migraine. <i>Journal of Headache and Pain</i> , 2006, 7, 433-437. | 2.5 | 13 |
| 162 | Closure of Patent Foramen Ovale and Cryptogenic Stroke: Unresolved Issues. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 92. | 2.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. <i>Journal of Stroke</i> , 2016, 18, 138-145. | 1.4 | 13 |
| 164 | A Review of Current Treatments for Migraine. <i>European Neurology</i> , 1994, 34, 18-25. | 0.6 | 12 |
| 165 | Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials. <i>European Journal of Neurology</i> , 2022, 29, 350-357. | 1.7 | 12 |
| 166 | Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source – Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. <i>Circulation Journal</i> , 2020, 84, 2286-2295. | 0.7 | 12 |
| 167 | Dipyridamole and headache. <i>Future Neurology</i> , 2007, 2, 279-283. | 0.9 | 11 |
| 168 | Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020, 9, 1969. | 1.0 | 11 |
| 169 | No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study. <i>Cephalalgia</i> , 2022, 42, 335-344. | 1.8 | 11 |
| 170 | Drug Treatment of Cluster Headache. <i>Drugs</i> , 2022, 82, 33-42. | 4.9 | 11 |
| 171 | Analgesics. <i>Current Medical Research and Opinion</i> , 2001, 17, s13-16. | 0.9 | 10 |
| 172 | Sumatriptan in the Treatment of Cluster Headache. <i>Cephalalgia</i> , 2001, 21, 16-17. | 1.8 | 10 |
| 173 | Consistent Efficacy, Tolerability, and High Levels of Satisfaction With Almotriptan 12.5 mg When Used to Treat Multiple Migraine Attacks in Routine Clinical Practice. <i>Headache</i> , 2005, 45, 624-631. | 1.8 | 10 |
| 174 | Headache attributed to a substance or its withdrawal. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 589-599. | 1.0 | 10 |
| 175 | Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the Amplatzer Amulet Observational Post-Market Study. <i>EuroIntervention</i> , 2021, 17, 774-782. | 1.4 | 10 |
| 176 | Source of cerebral microembolic signals in occlusion of the internal carotid artery. <i>Journal of Neurology</i> , 1997, 244, 312-317. | 1.8 | 9 |
| 177 | Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg. <i>Current Medical Research and Opinion</i> , 2005, 21, 1603-1610. | 0.9 | 9 |
| 178 | Effectiveness and Satisfaction with Zolmitriptan 5mg Nasal Spray for Treatment of Migraine in Real-Life Practice. <i>Clinical Drug Investigation</i> , 2007, 27, 59-66. | 1.1 | 9 |
| 179 | Antiplatelet therapy in secondary stroke prevention – state of the art. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2552-2560. | 1.6 | 9 |
| 180 | Headache attributed to non-vascular intracranial disorder. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 547-587. | 1.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study. <i>International Journal of Cardiology</i> , 2022, 363, 56-63. | 0.8 | 9 |
| 182 | Secondary Stroke Prevention with Antiplatelet Drugs: Have We Reached the Ceiling?. <i>International Journal of Stroke</i> , 2006, 1, 4-8. | 2.9 | 8 |
| 183 | CGRP antibodies for migraine prevention – new kids on the block. <i>Nature Reviews Neurology</i> , 2019, 15, 129-130. | 4.9 | 8 |
| 184 | Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958. | 1.0 | 8 |
| 185 | Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. <i>European Stroke Journal</i> , 2022, 7, 92-98. | 2.7 | 8 |
| 186 | The PROFESS trial: future impact on secondary stroke prevention. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1085-1091. | 1.4 | 7 |
| 187 | Rationale and design of a global registry to evaluate real-world clinical outcomes in patients with atrial fibrillation and high risk of stroke treated with left atrial appendage occlusion using the AMPLAZER amulet device – Perspective of available/ongoing registries of catheter-based LAA occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 540-547. | 0.7 | 7 |
| 188 | Cryptogenic stroke and patent foramen ovale (abridged and translated version). <i>Neurological Research and Practice</i> , 2019, 1, 1. | 1.0 | 7 |
| 189 | Antiplatelet drugs in secondary prevention of stroke. <i>Neurology</i> , 1997, 49, S75-81. | 1.5 | 7 |
| 190 | Left atrial appendage occlusion for ischemic stroke prevention in patients with non-valvular atrial fibrillation: clinical expert opinion and consensus statement for the Asian-Pacific region. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 61, 269-281. | 0.6 | 6 |
| 191 | Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. <i>PLoS ONE</i> , 2021, 16, e0249524. | 1.1 | 6 |
| 192 | Myopathy in two siblings with nephropathic cystinosis. <i>European Journal of Neurology</i> , 1998, 5, 609-612. | 1.7 | 5 |
| 193 | How Much Esprit Is in ESPRIT?. <i>Stroke</i> , 2006, 37, 2856-2857. | 1.0 | 5 |
| 194 | Patent foramen ovale, migraine and stroke: no reason to intervene. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 176-177. | 3.3 | 5 |
| 195 | Efficacy of NeuroFlo Device in Treatment of Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 1457-1461. | 0.7 | 5 |
| 196 | Preventing major gastrointestinal bleeding in elderly patients. <i>Lancet</i> , The, 2017, 390, 435-437. | 6.3 | 5 |
| 197 | Short Latency Gray Matter Changes in Voxel-Based Morphometry following High Frequent Visual Stimulation. <i>Neural Plasticity</i> , 2017, 2017, 1-6. | 1.0 | 5 |
| 198 | Closure of the patent foramen ovale in patients with embolic stroke of undetermined source: A clinical expert opinion and consensus statement for the Asian-Pacific region. <i>International Journal of Stroke</i> , 2020, 15, 937-944. | 2.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | CGRP-targeted drugs for migraine: still many uncertainties. <i>Lancet Neurology</i> , The, 2022, 21, 209-210. | 4.9 | 5 |
| 200 | Antiplatelet drugs in secondary prevention of stroke. <i>International Journal of Clinical Practice</i> , 1998, 52, 91-7. | 0.8 | 5 |
| 201 | Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. <i>International Journal of Clinical Practice</i> , 2000, 54, 670-4. | 0.8 | 5 |
| 202 | Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115. | 1.8 | 5 |
| 203 | Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, . | 1.6 | 5 |
| 204 | Limitations of PET and lesion studies in defining the role of the human cerebellum in motor learning. <i>Behavioral and Brain Sciences</i> , 1996, 19, 477. | 0.4 | 4 |
| 205 | Antithrombotic secondary prevention after stroke. <i>Current Treatment Options in Neurology</i> , 2001, 3, 451-462. | 0.7 | 4 |
| 206 | Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2019, 39, 1058-1066. | 1.8 | 4 |
| 207 | Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation. <i>Cephalalgia</i> , 2021, 41, 148-155. | 1.8 | 4 |
| 208 | Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 218. | 1.4 | 4 |
| 209 | Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. <i>Cephalalgia</i> , 2022, 42, 769-780. | 1.8 | 4 |
| 210 | Cerebellar ataxia. , 2001, , 48-59. | | 3 |
| 211 | Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke: The Potential Mechanisms and Therapeutic Implications. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005, 2, 53-57. | 0.7 | 3 |
| 212 | Response to Letter by Larsen et al. <i>Stroke</i> , 2006, 37, 1358-1358. | 1.0 | 3 |
| 213 | Primary and Secondary Stroke Prevention with Antiplatelet Drugs. <i>Current Pharmaceutical Design</i> , 2006, 12, 1293-1297. | 0.9 | 3 |
| 214 | Migraine: an endemic disease inside the blood-brain barrier. <i>Future Neurology</i> , 2009, 4, 405-420. | 0.9 | 3 |
| 215 | The cause of stroke matters for secondary prevention. <i>Lancet Neurology</i> , The, 2017, 16, 256-257. | 4.9 | 3 |
| 216 | Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. <i>Pain and Therapy</i> , 2020, 9, 683-694. | 1.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks. <i>Cephalalgia</i> , 2020, 40, 1331-1335. | 1.8 | 3 |
| 218 | The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. <i>Pain and Therapy</i> , 2020, 9, 695-707. | 1.5 | 3 |
| 219 | Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. <i>Cephalalgia</i> , 2021, 41, 1262-1267. | 1.8 | 3 |
| 220 | Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application. <i>Trials</i> , 2022, 23, 382. | 0.7 | 3 |
| 221 | Update on clopidogrel and dual anti-platelet therapy: neurology. <i>Country Review Ukraine</i> , 2006, 8, G15-G19. | 0.8 | 2 |
| 222 | Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs - is antiplatelet monotherapy still reasonable?. <i>International Journal of Clinical Practice</i> , 2011, 65, 531-535. | 0.8 | 2 |
| 223 | Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. <i>Europace</i> , 2021, 23, 65-72. | 0.7 | 2 |
| 224 | Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 152-157. | 0.4 | 2 |
| 225 | Headache secondary to cerebrovascular disease. <i>Cephalalgia</i> , 2021, 41, 479-492. | 1.8 | 2 |
| 226 | Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study. <i>European Stroke Journal</i> , 2021, 6, 438-444. | 2.7 | 2 |
| 227 | Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review. <i>Frontiers in Neurology</i> , 2022, 13, 864689. | 1.1 | 2 |
| 228 | A new CHANCE for combination antiplatelet therapy?. <i>Nature Reviews Neurology</i> , 2013, 9, 549-550. | 4.9 | 1 |
| 229 | Treating medication overuse headache: More than improving headache. <i>Cephalalgia</i> , 2014, 34, 405-406. | 1.8 | 1 |
| 230 | Comment on: "Phytomedicines in the Treatment of Migraine". <i>CNS Drugs</i> , 2019, 33, 615-615. | 2.7 | 1 |
| 231 | Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021, 05, e35-e42. | 0.7 | 1 |
| 232 | Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance. <i>Cephalalgia</i> , 2021, 41, 033310242110146. | 1.8 | 1 |
| 233 | Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. <i>European Journal of Internal Medicine</i> , 2021, 91, 75-80. | 1.0 | 1 |
| 234 | A history of International Headache Society grants and their impact on headache careers. <i>Cephalalgia</i> , 2022, 42, 1288-1293. | 1.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | A Review of Recent Clinical Experience with Almotriptan. <i>Drugs</i> , 2006, 66, 17-25. | 4.9 | 0 |
| 236 | Reply to "topiramate for migraine prophylaxis: addressing the blood-brain barrier-related pharmacokinetic pathophysiological disconnect". <i>International Journal of Clinical Practice</i> , 2006, 60, 368-369. | 0.8 | 0 |
| 237 | Is stenting a safe alternative to endarterectomy in patients with severe symptomatic carotid stenosis?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 190-191. | 2.7 | 0 |
| 238 | Response to Letter by Dame. <i>Stroke</i> , 2010, 41, . | 1.0 | 0 |
| 239 | What triggers migraine aura?. <i>Cephalalgia</i> , 2016, 36, 501-502. | 1.8 | 0 |
| 240 | Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves. <i>Stroke</i> , 2017, 48, 3183-3186. | 1.0 | 0 |
| 241 | Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. <i>Future Neurology</i> , 2020, 15, FNL48. | 0.9 | 0 |
| 242 | Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks. <i>Cephalalgia</i> , 2021, , 033310242110299. | 1.8 | 0 |
| 243 | Patent Foramen Ovale Closure "Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke. <i>US Neurology</i> , 2020, 16, 54. | 0.2 | 0 |
| 244 | 2021... OnabotA for CM: benefits beyond headache-day reduction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A73.1-A73. | 0.9 | 0 |